In a world orbited on clinical trial stratification and genetic breakthrough, the identification of the genetic distribution of APOE4 variants within ethnicities and latitudes may aid in elucidating its role in leading AD pathogenesis and contribute to the development of more targeted therapeutic approaches. This evidence concerns the gene APOE and Alzheimer disease.